Home Featured Page 12

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term...

Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the...

Paul Gillis-Smith – Psychedelics, Religion & Lisa Bieberman

FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms,...

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024

Reflections on the 2025 Federal Policy Summit on Psychedelic Medicine

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as...

Dr Simon Ruffell – Other Ways of Knowing

1...111213...299 Page 12 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar

Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term...

Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the...

Paul Gillis-Smith – Psychedelics, Religion & Lisa Bieberman

FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms,...

The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024

Reflections on the 2025 Federal Policy Summit on Psychedelic Medicine

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as...

Dr Simon Ruffell – Other Ways of Knowing

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY